In this section:

Myelodysplastic Syndromes Efficacy

In transfusion-dependent, lower-risk MDS

EXJADE Reduces the Burden of Iron Toxicity

EXJADE offers serum ferritin reductions as early as 3 months that continue with treatment

Median Serum Ferritin Reductions
EXJADE® Can Reduce Serum Ferritin in 3 Months

Data from the 1-year, multicenter, open-label, prospective EPIC study in patients with transfusion-dependent anemias (N=1744), including 341 with varying risk levels of myelodysplastic syndrome receiving treatment with EXJADE.

Learn more about this study
EXJADE REMOVES HEPATIC IRON

EXJADE demonstrated reductions in liver iron concentration.

Learn more

EXJADE SAFETY PROFILE ACROSS ANEMIAS

Learn more